Infliximab therapy decreases the levels of TNF-alpha and IFN-gamma mRNA in colonic mucosa of ulcerative colitis.
about
Clinical use and mechanisms of infliximab treatment on inflammatory bowel disease: a recent updateMolecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseasesHeat shock protein-derived T-cell epitopes contribute to autoimmune inflammation in pediatric Crohn's disease.Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience.Review article: the role of oxidative stress in pathogenesis and treatment of inflammatory bowel diseases.Quantification of biological network perturbations for mechanistic insight and diagnostics using two-layer causal models.Distinct IFNG methylation in a subset of ulcerative colitis patients based on reactivity to microbial antigens.Drug delivery technologies for autoimmune disease.Candidate mucosal and surrogate biomarkers of inflammatory bowel disease in the era of new technology.Pre- and posttherapy assessment of intestinal soluble mediators in IBD: where we stand and future perspectives.Role in calcineurin inhibitors for inflammatory bowel disease in the biologics era: when and how to use.Mucosal healing in the era of biologic agents in treatment of inflammatory bowel disease.Role of PECAM-1 in radiation-induced liver inflammation.The anti-TNF-α antibody infliximab indirectly regulates PECAM-1 gene expression in two models of in vitro blood cell activation.Global mucosal and serum cytokine profile in patients with ulcerative colitis undergoing anti-TNF therapy.Role of miR-19a targeting TNF-α in mediating ulcerative colitis.Gene expression profiling and response signatures associated with differential responses to infliximab treatment in ulcerative colitis.Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's disease.Tissue Drug Concentrations of Anti-tumor Necrosis Factor Agents Are Associated with the Long-term Outcome of Patients with Crohn's Disease.Infliximab inhibits activation and effector functions of peripheral blood T cells in vitro from patients with clinically active ulcerative colitis.No association between the SOCS-1 -1478CA/del polymorphism and ulcerative colitis in Turkish subjects.Elevation of PRKCDBP, a novel transcriptional target of TNF-α, and its downregulation by infliximab in patients with ulcerative colitis.Short-and Long-Term Clinical Outcomes of Infliximab in Fulminant Ulcerative Colitis
P2860
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
P2860
Infliximab therapy decreases the levels of TNF-alpha and IFN-gamma mRNA in colonic mucosa of ulcerative colitis.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Infliximab therapy decreases t ...... mucosa of ulcerative colitis.
@en
Infliximab therapy decreases t ...... mucosa of ulcerative colitis.
@nl
type
label
Infliximab therapy decreases t ...... mucosa of ulcerative colitis.
@en
Infliximab therapy decreases t ...... mucosa of ulcerative colitis.
@nl
prefLabel
Infliximab therapy decreases t ...... mucosa of ulcerative colitis.
@en
Infliximab therapy decreases t ...... mucosa of ulcerative colitis.
@nl
P2093
P2860
P1476
Infliximab therapy decreases t ...... mucosa of ulcerative colitis.
@en
P2093
Guanglin Cui
Jon Florholmen
Trine Olsen
P2860
P304
P356
10.1080/00365520902803507
P577
2009-01-01T00:00:00Z